AFFYMAX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0007 USD | -.--% |
|
-.--% | +16.67% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2012 | 94.37M 7.88B | Sales 2013 | 1.37M 114M | Capitalization | 29.24M 2.44B |
|---|---|---|---|---|---|
| Net income 2012 | -93M -7.76B | Net income 2013 | -14M -1.17B | EV / Sales 2012 | 6.75 x |
| Net cash position 2012 | 69.14M 5.77B | Net cash position 2013 | 5.6M 467M | EV / Sales 2013 | 17.3 x |
| P/E ratio 2012 |
-7.39
x | P/E ratio 2013 |
-2.03
x | Employees | 2 |
| Yield 2012 * |
-
| Yield 2013 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| 6 months | +75.00% | ||
| Current year | +16.67% |
1 week
0.00
0.00
1 month
0.000.00
Current year
0.000.00
1 year
0.000.04
3 years
0.000.09
5 years
0.000.26
10 years
0.000.74
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 0.0007 | -.--% | 41,017 |
Delayed Quote OTC Markets, April 30, 2024 at 08:43 pm IST
More quotes
Affymax, Inc. is a biopharmaceutical company. The Companyâs product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Companyâs product, OMONTYS.
| 1st Jan change | Capi. | |
|---|---|---|
| +16.67% | 26.24K | |
| +25.69% | 47.9B | |
| +47.24% | 41.42B | |
| -3.46% | 40.7B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- AFFY Stock